Immunotherapy targeting immune check-point(s) in brain metastases

Area of Science:

• Neuro-oncology
• Immunology
• Medical Oncology

Background:

• Monoclonal antibodies (mAb) targeting immune checkpoints have transformed cancer treatment, improving response rates and survival.
• Brain metastases and primary brain tumors remain challenging, with limited effective therapeutic options.
• Emerging evidence suggests immunotherapy may benefit patients with central nervous system (CNS) tumors.

Purpose of the Study:

• To review current immunotherapeutic strategies for brain metastases and primary brain tumors.
• To discuss challenges and potential solutions for CNS immunotherapy.
• To highlight future directions in the field.

Main Methods:

• Literature review of ongoing clinical trials and preclinical studies.
• Analysis of immunotherapy efficacy in CNS malignancies.
• Discussion of biological hurdles and therapeutic strategies.

Main Results:

• Immunotherapy demonstrates potential in treating brain metastases across various histotypes.
• Early data suggests efficacy in primary brain tumors, prompting further investigation.
• Multimodality approaches combining immunotherapy with other treatments are being explored.

Conclusions:

• Cancer immunotherapy holds promise for CNS tumors, but requires further validation.
• Overcoming biological and clinical challenges is crucial for successful implementation.
• Future research should focus on optimizing immunotherapy for brain metastases and primary brain tumors.